Hormonal
Continuous positive airway pressure (CPAP) therapy effectively reverses sleep-related disordered breathing and daytime symptoms, and mitigates acute pathophysiologic responses such as sympathetic activation and endothelin elevation, though long-term cardiovascular mortality benefits remain unproven.
If you have been diagnosed with Obstructive Sleep Apnea, CPAP is the most effective treatment to stop breathing interruptions and reduce daytime sleepiness. While it may not yet be proven to extend life expectancy in heart failure patients, it significantly improves cardiovascular markers like blood pressure and sympathetic activity. If you struggle with the mask, ask your provider about heated humidification or nasal sprays to improve comfort and adherence.
Continuous positive airway pressure (CPAP) is very effective at reversing sleep-related disordered breathing events and consequent daytime symptoms... The role of CPAP and other modes of therapy in the management of systemic disease that coexists with obstructive sleep apnea is promising but remains to be determined by rigorous interventional controlled trials.
Why this rating
The paper cites rigorous longitudinal cohort studies for diagnosis and small randomized trials for CPAP effects, but notes a lack of large-scale RCTs for mortality.
Source
Obstructive Sleep Apnea
Sean M. Caples et al. · Annals of Internal Medicine · 2005
DOI 10.7326/0003-4819-142-3-200502010-00010
More from this paper
- Obstructive Sleep Apnea is causally linked to the development of systemic hypertension, with worsening AHI independently associated with an increasing risk of new hypertension, even in mild cases.Strong
- Weight loss of approximately 10% in overweight patients with OSA leads to clinically significant improvement in the Apnea-Hypopnea Index, although it rarely normalizes the index completely.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →